Malickova Karin, Kratka Zuzana, Luxova Stepanka, Bortlik Martin, Lukas Milan
Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s, Prague, Czech Republic.
Immunological Laboratory, GENNET, Prague, Czech Republic.
Scand J Gastroenterol. 2020 Aug;55(8):917-919. doi: 10.1080/00365521.2020.1791244. Epub 2020 Jul 14.
Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide triggering a pandemic during the year 2020. The proportion of persons infected with SARS-CoV-2 whose infection remained subclinical is not known. However, such information is important to determine whether the control measures currently employed are sufficient to halt the spread of the virus. Current study has examined the seroprevalence of anti-SARS-CoV-2 antibodies in a population of 92 healthcare professionals working with patients with inflammatory bowel disease (IBD). The enzyme-linked immunosorbent assay (ELISA) test system for SARS-CoV-2 IgG from EUROIMMUN Medizinische Labordiagnostika AG (Germany) was used. Very low herd antibody-mediated immunity was proven, less than 2%, although we have been faced with the COVID-19 pandemic for several months. Anti-SARS-CoV-2 IgG antibody testing is currently unable to provide sufficient information about our anti-infectious immunity.
2019年冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，于2020年在全球范围内传播，引发了一场大流行。感染SARS-CoV-2但感染仍处于亚临床状态的人群比例尚不清楚。然而，此类信息对于确定当前采用的控制措施是否足以阻止病毒传播至关重要。当前研究检测了92名从事炎症性肠病（IBD）患者治疗工作的医护人员群体中抗SARS-CoV-2抗体的血清流行率。使用了德国EUROIMMUN Medizinische Labordiagnostika AG公司的SARS-CoV-2 IgG酶联免疫吸附测定（ELISA）检测系统。尽管我们已经面临COVID-19大流行数月，但结果显示群体抗体介导的免疫力非常低，不到2%。目前，抗SARS-CoV-2 IgG抗体检测无法提供足够关于我们抗感染免疫力的信息。
